-+ 0.00%
-+ 0.00%
-+ 0.00%

2026 IMS ORAL PRESENTATION: INNOVENT ANNOUNCES UPDATED PHASE 1 CLINICAL DATA OF TRISPECIFIC ANTIBODY IBI3003 (GPRC5D/BCMA/CD3) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

Reuters·09/29/2026 07:45:49

Please log in to view news